2017 ~ 2024
- 2024
- · EPD Biotherapeutics Inc. merger
- · Efesa product launched in Indonesia
- 2023
- · Completion of Phase 3 Trials for GX-H9, a Long-Acting Growth Hormone Deficiency Treatment for Pediatric Patients
- 2022
- · Moved into Bio Innovation Park (Magok)
- 2021
- · Technology transfer to KGBio (Indonesia) (GX-I7)
- 2020
- · Technology transfer to Genenbio (GX-P1, GX-P10)
- 2019
- · GX-188E, Phase 2 clinical trial and entry
- 2018
- · Korean clinical trial 1b/2a approval for concurrent administration of immune checkpoint inhibitors for triple-negative breast cancer patients
- · US Roche, NIT signed a contract for joint clinical development of HyLeukin-7&immune checkpoint inhibitor combination therapy
- 2017
- · I-Mab (merged 3rd Venture and Tasgen) Technology transfer (GX-I7)
2010 ~ 2016
- 2016
- · Technology transfer to Chemowanbang (GX-E4)
- 2015
- · Technology transfer to Tasgen (Tasly and J.V.) (H9, G6, G3)
- · Technology transfer to NIT (GX-188E, GX-I7)
- 2014
- · igned a biopharmaceutical development agreement with Hebang
- 2013
- · Technology transfer to ILKOGEN (ILKO and J.V) (GX-G3)
- 2012
- · Technology transfer to Handok (GX-H9)
1999 ~ 2009
- 2009
- · Listed on the KOSDAQ by special technology
- 2008
- · Technology transfer to Ildong Pharmaceutical Company (GX-G6)
- 2006
- · hyFc development and joint R&D with Dong-A Pharmaceutical Company
- 2005
- · Started phase 1 clinical trial for hepatitis B treatment
- 1999
- · Established Genexine Co., Ltd. (Gene + Vaccine)